福萊特玻璃(06865.HK)就實施“福萊轉債”贖回第三次提示
格隆匯 1 月 27日丨福萊特玻璃(06865.HK)公吿,關於實施“福萊轉債”贖回的第三次提示,重要內容提示:贖回登記日:2021年1月29日;贖回價格:100.274元/張;贖回款發放日:2021年2月1日;贖回登記日次一交易日起,“福萊轉債”將停止交易和轉股;本次提前贖回完成後,“福萊轉債”將在上海證券交易所摘牌。
截至2021年1月27日收市後,“福萊轉債”收盤價為289.14元/張。根據贖回安排,截至2021年1月29日收市後尚未實施轉股的“福萊轉債”將按照100.274元/張的價格提前贖回,因目前二級市場價格與贖回價格差異較大,投資者如未及時轉股或未賣出轉債,可能面臨損失。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.